Clinical Trial

Cereboost (American Ginseng Extract) and Brain Function

Study acronym: REACT

Terminated

View on ClinicalTrials.gov →

Why the trial stopped

Rate of recruitment was really low and it was decided to close the Norwich site

Summary

The study will assess the immediate, short-term benefits of a single dose of a supplement containing 200mg of Panax quinquefolius (American Ginseng) on cognition (brain function) in healthy young adults. To understand the effect this product may have, the participants will complete a series of questionnaires and cognitive tests (tests of memory and brain function) at set intervals across a 6-hour period. Blood samples will also be collected to assess the impact of the study product on the participants.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-11-20; most recent amendment 2026-06-23.

Status change: Recruiting → Terminated 2026-06-23

Status change: Not Yet Recruiting → Recruiting 2025-12-01

Trial Details

NCT Number	NCT07255755
Lead Sponsor	University of East Anglia Collaborators: Givaudan France Naturals, Atlantia Food Clinical Trials
Conditions	Attention, Cognition
Enrollment	27 participants
Start Date	2025-12-01
Primary Completion	2026-06-15 (estimated)
Study Completion	2026-06-15 (estimated)
Updated on ClinicalTrials.gov	2026-06-26